Posted by Michael Wonder on 27 Jul 2016
CADTH calls for patient input on submission from Pierre Fabre for Hemangiol (propranolol hydrochloride)
27 July 2016 - CADTH has received notice of a pending submission from Pierre Fabre for Hemangiol (propranolol hydrochloride).
CADTH is expecting a submission from Pierre Fabre late next month for propranolol hydrochloride oral solution for the treatment of children with infantile haemangioma.
This will be the second submission from Pierre Fabre for Hemangiol; the first was withdrawn in early 2015.
